1. Novo Nordisk. Data on file. 2. UNICEF. The state of the world's children 2019. Available at: https://www.unicef.org/media/60806/file/SOWC-2019.pdf [https://www.unicef.org/media/60806/file/SOWC-2019.pdf]. Last accessed: March 2021. 3. Abarca-Gómez L, Abdeen ZA, Hamid ZA, et al. Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 1289 million children, adolescents, and adults. The Lancet. 2017; 390:2627-2642. 4. World Health Organization. Obesity and Overweight Factsheet no. 311. Available at: http://www.who.int/mediacentre/factsheet... [http://www.who.int/mediacentre/factsheet...]. Last accessed: March 2021. 5. World Health Organization. Childhood overweight and obesity. Available at: https://www.who.int/dietphysicalactivity... [https://www.who.int/dietphysicalactivity...]. Last accessed: March 2021. 6. EMA. Saxenda (liraglutide 3 mg) summary of product characteristics. Available at: https://www.ema.europa.eu/en/documents/product-information/s... roduct-information_en.pdf [https://www.ema.europa.eu/en/documents/product-information/s...- product-information_en.pdf]. Last accessed: March 2021. 7. Kelly AS, Auerbach P, Barrientos-Perez M, et al. A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity. N Engl J Med. 2020; 382:2117-2128. 8. EMA. Paediatric investigation plans. Available at: https://www.ema.europa.eu/en/human-regulatory/research-devel... tric-medicines/paediatric-investigation-plans [https://www.ema.europa.eu/en/human-regulatory/research-devel... atric-medicines/paediatric-investigation-plans]. Last accessed: March 2021. 9. EMA. On the acceptance of a modification of an agreed paediatric investigation plan for liraglutide (Saxenda). Available at: https://www.ema.europa.eu/en/documents/pip-decision/p/0154/2... ion-15-june-2016-acceptance-modification-agreed-paediatric-investigation- plan_en.pdf [https://www.ema.europa.eu/en/documents/pip-decision/p/0154/2... sion-15-june-2016-acceptance-modification-agreed-paediatric-investigation -plan_en.pdf]. Last accessed: March 2021. 10. Novo Nordisk Canada. Saxenda() (liraglutide 3 mg) Canada Product Monograph. Available at: http://www.novonordisk.ca/content/dam/Canada/AFFILIATE/www-n... a/OurProducts/PDF/Saxenda_PM_English.pdf [http://www.novonordisk.ca/content/dam/Canada/AFFILIATE/www-n...- ca/OurProducts/PDF/Saxenda_PM_English.pdf]. Last accessed: March 2021. 11. Orskov C, Wettergren A and JJ H. Secretion of the incretin hormones glucagon-like peptide-1 and gastric inhibitory polypeptide correlates with insulin secretion in normal man throughout the day. Scandinavian Journal of Gastroenterology. 1996; 31:665-670. 12. FDA. Saxenda (liraglutide 3 mg) prescribing information. Available at: https://www.accessdata.fda.gov/drugsatfd.... pdf [https://www.accessdata.fda.gov/drugsatfd... .pdf]. Last accessed: March 2021. 13. American Medical Association. A.M.A Adopts New Policies on Second Day of Voting at Annual Meeting. Obesity as a Disease. Available at: http://news.cision.com/american-medical-association/r/ama-ad... icies-on-second-day-of-voting-at-annual-meeting,c9430649 [http://news.cision.com/american-medical-association/r/ama-ad... licies-on-second-day-of-voting-at-annual-meeting,c9430649]. Last accessed: March 2021. 14. Bray GA, Kim KK, Wilding JPH, et al. Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation. Obes Rev. 2017; 18:715-723. 15. Wright SM and Aronne LJ. Causes of obesity. Abdom Imaging. 2012; 37:730-732. 16. HE Bays, W McCarthy, S Christensen, et al. Obesity Algorithm, presented by the Obesity Medicine Association. Available at: https://obesitymedicine.org/obesity-algorithm/ [https://obesitymedicine.org/obesity-algorithm/]. Last accessed: March 2021. 17. Lifshitz F. Obesity in Children. J Clin Res Pediatr Endocrinol. 2008; 1:53-60.
CONTACT: Further Information, Media: Mette Kruse Danielsen, +45 3079 3883,mkd@novonordisk.com. Michael Bachner (US), +1 609 664 7308,mzyb@novonordisk.com. Investors: Daniel Muusmann Bohsen, +45 3075 2175,dabo@novonordisk.com. Valdemar Borum Svarrer, +45 3079 0301,jvls@novonordisk.com. Ann Sndermlle Rendbk, +45 3075 2253,arnd@novonordisk.com. Mark Joseph Root, +45 3079 4211,mjhr@novonordisk.com. Kristoffer Due Berg (US), +1 609 235 2989,krdb@novonordisk.com
Web site: https://www.novonordisk.com/
